The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

On Jan. 30, the U.S. Food and Drug Administration (FDA) approved a new drug called suzetrigine to treat moderate-to-severe pain. The prescription pills, sold under the brand name Journavx and made ...

The drug, suzetrigine, is a 50-milligram prescription ... acting director of the FDA’s Center for Drug Evaluation and ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain medicine in the US in more than 20 years. The oral NaV1.8 inhibitor has been ...

Vertex Pharma has filed for FDA approval of its non-opioid pain drug suzetrigine, starting the clock ticking on a review that should be completed early next year. The FDA has granted a priority ...

The FDA’s January 2025 approval of Journavx (suzetrigine), a non-opioid oral pain treatment, further contributed to the company’s market capitalisation growth. Gilead Sciences witnessed a ...